The Mylan EpiPen Debacle: How Tremendous Greed Can Lead to the Demise of a Leader
N2Growth Blog
AUGUST 30, 2016
As you have likely heard, the pharmaceutical company Mylan and its CEO, Heather Bresch, have come under immense scrutiny for the firm’s EpiPen pricing policy. And against that, manufacturing the product, distributing the product, enhancing the product, investing.” It costs something to develop the product.
Let's personalize your content